EP 3204031 A2 20170816 - NEW USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF VARIOUS DISEASES
Title (en)
NEW USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF VARIOUS DISEASES
Title (de)
VERWENDUNG VON ZELLDURCHLÄSSIGEN PEPTIDHEMMERN DES JNK-SIGNALTRANSDUKTIONSWEGES ZUR BEHANDLUNG VERSCHIEDENER KRANKHEITEN
Title (fr)
NOUVELLE UTILISATION D'INHIBITEURS PEPTIDIQUES PERMÉABLES AUX CELLULES DE LA VOIE DE TRANSDUCTION DU SIGNAL JNK POUR LE TRAITEMENT DE DIVERSES MALADIES
Publication
Application
Priority
- EP 2014002724 W 20141008
- EP 2015001294 W 20150626
- EP 2015001974 W 20151008
Abstract (en)
[origin: WO2016055160A2] The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.
IPC 8 full level
A61K 38/17 (2006.01); A61K 48/00 (2006.01); A61P 3/10 (2006.01); A61P 13/10 (2006.01); A61P 13/12 (2006.01); A61P 25/28 (2006.01); A61P 41/00 (2006.01); C07K 14/47 (2006.01); C07K 16/40 (2006.01); C12N 15/00 (2006.01)
CPC (source: EP)
A61K 38/1709 (2013.01); A61P 3/10 (2017.12); A61P 13/10 (2017.12); A61P 13/12 (2017.12); A61P 25/28 (2017.12); A61P 41/00 (2017.12); C07K 14/4703 (2013.01); C12N 9/1205 (2013.01); C12N 15/00 (2013.01); Y02A 50/30 (2017.12)
Citation (search report)
See references of WO 2016055160A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2016055160 A2 20160414; WO 2016055160 A3 20160630; EP 3204031 A2 20170816
DOCDB simple family (application)
EP 2015001974 W 20151008; EP 15778614 A 20151008